A Phase 3 Trial of Bevacizumab in Ovarian Cancer

20112,134 citationsJournal Articlebronze Open Access

Authors

Timothy Perren · St James's University Hospital

Ann Marie Swart · Medical Research Council

Jacobus Pfisterer · Städtisches Klinikum Solingen

Jonathan A. Ledermann · University College London

Éric Pujade-Lauraine · Assistance Publique – Hôpitaux de Paris

Gunnar B. Kristensen · Oslo University Hospital

Mark S. Carey

Abstract

Bevacizumab improved progression-free survival in women with ovarian cancer. The benefits with respect to both progression-free and overall survival were greater among those at high risk for disease progression. (Funded by Roche and others; ICON7 Controlled-Trials.com number, ISRCTN91273375.).

Topics & Keywords

Ovarian cancer diagnosis and treatment Phytochemical compounds biological activities Angiogenesis and VEGF in Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 365, Issue 26, pp. 2484-2496

DOI: 10.1056/nejmoa1103799

Field-Weighted Citation Impact: 162.40